LF
ITRM

Lee Financial’s Iterum Therapeutics ITRM Stock Holding History

Lee Financial’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,000
Closed -$19.7K – 151
2025
Q1 		$19.7K Hold
16,000
– – ﹤0.01% 144
2024
Q4 		$28.3K Buy
+16,000
New +$25.1K ﹤0.01% 180

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $723M AUM 24.23% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Lee Financial's ITRM Position: Q2 2025 in Review

Lee Financial sold out of Iterum Therapeutics (ITRM) in Q2 2025, closing a stake of 16,000 shares — an estimated $19.7K sold.

Lee Financial first reported a position in ITRM in Q4 2024 and held it in 2 quarters. The position peaked at $28.3K in Q4 2024. 24 funds tracked by Wall St. Rank hold ITRM as of Q2 2025.

  • Lee Financial reported no remaining Iterum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lee Financial sold 16,000 Iterum Therapeutics shares in Q2 2025, an estimated $19.7K.
  • Lee Financial first reported a position in Iterum Therapeutics in Q4 2024 and held it in 2 quarters.
  • Lee Financial's Iterum Therapeutics position peaked at $28.3K in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2025.

Based on Lee Financial's 13F filing for Q2 2025, filed 24 Jul 2025.